6325-41-3

Usage

Uses

Used in Food Industry:
3-methyl-3-phenyl-butanal is used as a flavoring agent for its fruity and floral aroma, enhancing the taste and smell of various food products.
Used in Perfume and Fragrance Industry:
It serves as a key ingredient in the production of perfumes and fragrances, contributing to the creation of complex and nuanced scents due to its strong, sweet, floral odor.
Used in Antimicrobial Applications:
3-methyl-3-phenyl-butanal has been studied for its potential antimicrobial properties, suggesting its use in applications where microbial control is necessary.
Used in Antioxidant Applications:
3-methyl-3-phenyl-butanal's potential antioxidant properties indicate its use in industries where protection against oxidative damage is required, such as in the food and cosmetic industries.

InChI:InChI=1/C11H14O/c1-11(2,8-9-12)10-6-4-3-5-7-10/h3-7,9H,8H2,1-2H3

Upstream product

• 67-66-3 chloroform 
• 515-40-2 neophyl chloride 
• 122-51-0 orthoformic acid triethyl ester 
• 35293-35-7 2-methyl-2-phenyl-1-propylmagnesium chloride 
• 2629-47-2 diphenylantimony(III) chloride 
• 556-82-1 3-methyl-2-buten-1-ol 
• 66622-39-7 4-methyl-4-phenylpent-1ene 
• 4394-85-8 4-morpholinecarboxaldehyde 
• 617-94-7 1-methyl-1-phenylethyl alcohol 
• 22881-48-7 2-phenylpropan-2-yl vinyl ether 
• 21438-74-4 3-methyl-3-phenylbutan-1-ol 
• 1010-48-6 3-methyl-3-phenylbutanoic acid 
• 3805-10-5 2,2-(dimethyl)-2-phenylacetaldehyde 

Downstream Products

• 253185-03-4 tert-butylbenzene 
• 538-93-2 1-phenyl-2-methylpropane 
• 4094-64-8 3-methyl-3-phenyl-butyryl chloride 
• 93137-16-7 3-methyl-3-phenyl-butyraldehyde-semicarbazone 
• 67-66-3 chloroform 
• 66622-39-7 4-methyl-4-phenylpent-1ene 
• 28793-11-5 ((E)-1,1,6-Trimethyl-hepta-3,5-dienyl)-benzene 
• 55106-22-4 Brom-2 methyl-3 phenyl-3 butanal 
• 136281-92-0 3-(2-phenylpropan-2-yl)-1H-indole 
• 881392-78-5 2-amino-4-methyl-4-phenyl-pentanoic acid 
• 17684-33-2 β,β-dimethyl-β-phenylpropionitrile 

Relevant academic research and scientific papers

Nickel-Catalyzed Selective Reduction of Carboxylic Acids to Aldehydes

The direct reduction of carboxylic acids to aldehydes is a fundamental transformation in organic synthesis. The combination of an air-stable Ni precatalyst, dimethyl dicarbonate as an activator, and silane reductant effects this reduction for a wide variety of substrates, including pharmaceutically relevant structures, in good yields and with no overreduction to alcohols. Moreover, this methodology is scalable, allows access to deuterated aldehydes, and is also compatible with one-pot utilization of the aldehyde products.

One-Pot Preparation of C1-Homologated Aliphatic Nitriles from Aldehydes through a Wittig Reaction under Metal-Cyanide-Free Conditions

A one-pot protocol to obtain C1-homologated aliphatic nitriles was achieved by treating aromatic and aliphatic aldehydes with the (methoxymethyl)triphenylphosphonium ylide followed by hydrolysis of the resulting methyl vinyl ethers with pTsOH (Ts = para-toluenesulfonyl) and treatment with molecular iodine and aqueous ammonia under metal cyanide free conditions. Neopentyl-type nitriles, which could not be obtained by conventional methods that involved conversion of the neopentyl alcohol into a tosylate and treatment with metal cyanide, were successfully obtained by using the present method.

Synthesis of 2-tetralone derivatives by Bi(OTf)3-catalyzed intramolecular hydroarylation/isomerization of propargyl alcohols

Compared to 1-tetralones, 2-tetralones are expensive, less stable, and difficult to synthesize. A concise Bi-catalyzed method was developed for the synthesis of 2-tetralones from 5-phenylpent-1-yn-3-ol derivatives. Diverse 2-tetralones were obtained in moderate to good yields under mild conditions.

Vinyl polymerization versus [1,3] O to C rearrangement in the ruthenium-catalyzed reactions of vinyl ethers with hydrosilanes

Two reactions, vinyl polymerization and [1,3] O to C rearrangement of vinyl ethers, are investigated in the ruthenium-catalyzed reaction with hydrosilanes. The reaction pathways are dependent on the substituents of the vinyl ether, in particular, those of the alkoxy group. Primary-, secondary-, and tertiary-alkyl vinyl ethers, ROCHCH2, are polymerized with ease to give the corresponding polymer in good yields. When R is electron-donating benzyl groups, the reaction does not give the polyvinyl ether but results in [1,3] O to C rearrangement to give the corresponding aldehyde, RCH2CHO in moderate to good yields. The rearrangement selectively proceeds when vinyl ethers having α-substituents are used as the starting materials to give the corresponding ketones in high yields. With catalytic amounts of hydrosilanes, the rearrangement gives ketones or aldehydes selectively. In sharp contrast, use of excess amounts of hydrosilanes leads to the rearrangement followed by reduction of the formed carbonyl group to give the corresponding silyl ethers in good yields. Nature of catalytically active species is discussed. Crown Copyright

PROCESSES AND INTERMEDIATES FOR PREPARING CYSTEINE PROTEASE INHIBITORS

The present invention is directed to a novel process for preparing certain cysteine protease inhibitors.

HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS

The application is directed to haloalkyl-substituted compounds of Formula (I), wherein R1, R1a, R2, R3, R4’ and E are as defined in the claims. The compounds are inhibitors of cysteine proteases, in p

AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceu

CYSTEINE PROTEASE INHIBITORS

The present invention is directed to compounds that are inhibitors of cysteine protease, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceut

PEPTIDIC COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.